

Vantage Radiology is pleased to be offering Illucix (GA 68 Gozetotide) for patients with suspected prostate cancer metastasis with high Prostate Specific Membrane Antigen (PSMA) levels. Illucix can also help determine whether your patient is appropriate for certain treatment that is PSMA-directed therapy.

Quick Facts about Illucix:

- Illucix with Gallium-68, is a radioactive diagnostic agent indicated for PET/CT imaging of prostate-specific membrane antigen-positive lesions in men with prostate cancer:
 - With suspected metastasis who are candidates for initial definitive therapy
 - With suspected recurrence based on elevated serum prostate-specific antigen (PSA) level
- A PET scan with Illucix may be able to detect cancer when PSA levels are low and when tumors are small or conventional imaging results are uncertain.
- PET Imaging has the potential to improve disease localization compared to standard imaging, thus enhancing therapeutic decision-making. (With an appropriate tracer and combined with CT or MRI.)^{4,5}
- PSMA PET/CT can detect lesions as small as 4 mm.
 - Because up to 80% of nodal metastases in PCa are smaller than 8 mm in size, PSMA PET/CT is a promising imaging modality.^{4,6}
- PSMA PET/CT is also effective at lower PSA levels compared to standard imaging.
- FDA approved
- CMS reimbursed

Patient prep: The patient will need to drink 20 oz of water to hydrate prior to the exam.

- Please advise the patient to come well-hydrated. Dehydration may affect the results of imaging.

Important things to note:

- The patient will need to hold still for the entire scan time on the table which can vary but is approximately 40 minutes.
 - They will be positioned on their back with pillows to support their neck and legs. If possible, their arms will be placed above their head.

How to order in Epic: Search - PET CT Prostate; IMG4063 (No spaces in study type off the facilities list.)

Illucix efficacy in clinical trials:

- Illucix PET/CT specificity averaged 90% in the PSMA-PreRP study.³
- Illucix PET/CT sensitivity scored 47% in the PSMA-PreRP study.³
- Illucix PET/CT negative predictive value (NPV) was 84% and the positive predictive value (PPV) was 61% in an open lab clinical study.³
- 74% of patients had one or more positive regions detected by Illucix. Regions detected were 34% bone, 25% pelvic lymph node, 25% prostate bed, and 17% extra pelvic soft tissue.²



1. Telix Pharmaceuticals. (2024b, March 5). Official website for Illucix® (kit for the preparation of Gallium GA 68 gozetotide injection). Illucix® (kit for the preparation of gallium Ga 68 gozetotide injection) - Patient Website. <https://illucix.com/>

2. Telix Pharmaceuticals. (2023, August 24). Healthcare Professional (HCP) site for Illucix® (kit for the preparation of gallium GA 68 gozetotide injection). Illucix® (kit for the preparation of gallium Ga 68 gozetotide injection) - Telix Pharmaceuticals. <https://illucixhcp.com/>

3. Telix Pharmaceuticals. (n.d.). Illucix - prescribing information. <http://illucixhcp.com/wp-content/uploads/illucix-prescribing-information.pdf>

4. MS, A. R. A. (n.d.). Guiding management of therapy in prostate cancer: Time to switch from conventional imaging to PSMA Pet?. Therapeutic advances in medical oncology. <https://pubmed.ncbi.nlm.nih.gov/31565073/>

5. Pienta KJ, Gorin MA, Rowe SP, et al. A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with 18F-DCFPyL in prostate cancer patients (OSPREY) [published online ahead of print, February 26, 2021]. J. Urol. doi: 10.1097/JU.0000000000001698

6. Hofman MS, Lawrentschuk N, Francis RJ, et al; proPSMA Study Group Collaborators. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208-1216. doi:10.1016/S0140-6736(20)30314-7